Immunoprecise Antibodies (IPA-TSX.V) has been on quite a run this year, and is up substantially since our first recommendation $1.50 ($0.30 pre-consolidation). At today's high of $26.25 that's an increase of 1,750%.

For the purpose of our track-record, we are encouraging our subscribers to take some profits. While we still expect it to move considerably higher, and this isn't a signal to read into from a fundamental perspective, we recognize it's prudent to take advantage of this recent parabolic move.

In light of this recent parabolic move we are capturing gains here and booking them for the Smallcap Discoveries Select Portfolio.